Edition:
United States

Ironwood Pharmaceuticals Inc (IRWD.OQ)

IRWD.OQ on NASDAQ Stock Exchange Global Select Market

18.08USD
18 May 2018
Change (% chg)

-- (--)
Prev Close
$18.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
449,709
52-wk High
$19.94
52-wk Low
$13.00

Select another date:

Mon, May 14 2018

BRIEF-Ironwood Pharma Sends Letter To Shareholders Highlighting Director Nominees

* IRONWOOD PHARMACEUTICALS SENDS LETTER TO SHAREHOLDERS HIGHLIGHTING DIRECTOR NOMINEES

BRIEF-Ironwood And Allergan Announce Settlement With Aurobindo Pharma Resolving Linzess Patent Litigation

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH AUROBINDO PHARMA RESOLVING LINZESS (LINACLOTIDE) PATENT LITIGATION

BRIEF-Ironwood Pharmaceuticals To Separate Into Two Independent, Publicly Traded Companies

* IRONWOOD PHARMACEUTICALS ANNOUNCES INTENT TO SEPARATE SOLUBLE GUANYLATE CYCLASE (SGC) BUSINESS FROM COMMERCIAL AND GASTROINTESTINAL BUSINESS

BRIEF-Ironwood Pharmaceuticals Reports Q1 Loss Per Share Of $0.29

* IRONWOOD PHARMACEUTICALS PROVIDES FIRST QUARTER 2018 INVESTOR UPDATE

BRIEF-Ironwood Announces Director Nomination From Sarissa Capital

* RECEIVED NOTICE FROM SARISSA CAPITAL MANAGEMENT LP OF INTENTION TO NOMINATE ALEX DENNER TO STAND FOR ELECTION Source text for Eikon: Further company coverage:

BRIEF-Ironwood Pharmaceuticals Qtrly GAAP Net Income Per Share $0.08

* EXPECTS TO USE LESS THAN $75 MILLION IN CASH FOR OPERATIONS IN 2018 ‍​ Source text for Eikon: Further company coverage:

BRIEF-Ironwood Pharmaceuticals Implements Reduction In Field-Based Workforce

* SAYS ‍COMMENCED AN INITIATIVE TO EVALUATE OPTIMAL MIX OF INVESTMENTS FOR LESINURAD FRANCHISE FOR UNCONTROLLED GOUT​

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

BRIEF-Ironwood Pharmaceuticals Sees U.S. Net Sales Of Linzess Of About $700 Million‍​ For FY Ended Dec 31, 2017

* IRONWOOD PHARMACEUTICALS INC - EXPECTED U.S. NET SALES OF LINZESS (LINACLOTIDE) OF ABOUT $700 MILLION‍​ FOR FY ENDED DEC 31, 2017

BRIEF-Ironwood Reports Top-Line Phase IIa Data For IW-1973

* IRONWOOD REPORTS TOP-LINE PHASE IIA DATA FOR IW-1973 DEMONSTRATING POSITIVE CARDIOVASCULAR, METABOLIC AND ENDOTHELIAL EFFECTS

Select another date: